• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Anilides Aromatic anilides
• Pharmaceutical and Biochemical Products Medical Disease Classifications
• Other Chemical Reagents

Mocetinostat (CAS No. 726169-73-9): A Promising Histone Deacetylase Inhibitor in Cancer Therapy

Mocetinostat (CAS No. 726169-73-9) is a potent and selective histone deacetylase (HDAC) inhibitor that has garnered significant attention in the field of cancer research. HDAC inhibitors are a class of drugs that have shown promise in modulating gene expression and inducing cell cycle arrest, apoptosis, and differentiation in various cancer types. This article provides an in-depth overview of Mocetinostat, including its mechanism of action, clinical applications, and recent advancements in its development.

Mocetinostat specifically targets class I and IV HDACs, which are overexpressed in many cancers. By inhibiting these enzymes, Mocetinostat can restore the acetylation levels of histone proteins, leading to changes in chromatin structure and gene expression. This mechanism is crucial for the regulation of tumor suppressor genes and oncogenes, making Mocetinostat a valuable tool in cancer therapy.

Recent studies have highlighted the efficacy of Mocetinostat in various preclinical models of cancer. For instance, a study published in the journal Cancer Research demonstrated that Mocetinostat significantly reduced tumor growth and induced apoptosis in human non-small cell lung cancer (NSCLC) cells. The researchers found that Mocetinostat not only inhibited HDAC activity but also enhanced the sensitivity of NSCLC cells to chemotherapy agents such as cisplatin.

In addition to its direct effects on cancer cells, Mocetinostat has shown potential as a combination therapy with other anticancer drugs. A clinical trial conducted by the National Cancer Institute (NCI) evaluated the safety and efficacy of Mocetinostat in combination with gemcitabine for the treatment of advanced solid tumors. The results indicated that this combination was well-tolerated and led to partial responses in several patients, suggesting a synergistic effect between the two drugs.

The pharmacokinetic properties of Mocetinostat have also been extensively studied. It has been shown to have good oral bioavailability and a favorable pharmacokinetic profile, making it suitable for chronic administration. A phase I clinical trial published in the journal Clinical Cancer Research reported that Mocetinostat was well-tolerated at doses up to 800 mg twice daily, with no dose-limiting toxicities observed. The most common adverse effects were mild to moderate gastrointestinal symptoms, which were manageable with supportive care.

Beyond its applications in solid tumors, Mocetinostat has also shown promise in hematological malignancies. A study published in the journal Blood investigated the effects of MocetinostatMocetinostatMocetinostat

The development of biomarkers to predict response to HDAC inhibitors like MocetinostatClinical Epigenetics identified several epigenetic markers associated with sensitivity to HDAC inhibition in breast cancer cells. These markers included hypermethylation of specific tumor suppressor genes and altered expression of microRNAs involved in cell cycle regulation. The identification of such biomarkers could help personalize treatment strategies and improve patient outcomes.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)